Evidence map›Paper›PMID 41416804›Full record

ArticleInfection and immunity2026

Grace Overman, Iris Loeckener, Zachary Williford, Sung Davis, Aissata Diallo, Josie Blair, Beate Henrichfreise, George W Liechti

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Infection and immunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. RNF213-dependent lytic destruction ofProceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Grace OvermanDepartment of Microbiology and Immunology, Uniformed Services University, Bethesda, Maryland, USA.
Iris LoeckenerInstitute for Pharmaceutical Microbiology, University of Bonn, Bonn, Germany.
Zachary WillifordDepartment of Microbiology and Immunology, Uniformed Services University, Bethesda, Maryland, USA.
Sung DavisDepartment of Microbiology and Immunology, Uniformed Services University, Bethesda, Maryland, USA.
Aissata DialloDepartment of Microbiology and Immunology, Uniformed Services University, Bethesda, Maryland, USA.
Josie BlairDepartment of Microbiology and Immunology, Uniformed Services University, Bethesda, Maryland, USA.
Beate HenrichfreiseInstitute for Pharmaceutical Microbiology, University of Bonn, Bonn, Germany.ORCID 0000-0001-9783-8157
George W LiechtiDepartment of Microbiology and Immunology, Uniformed Services University, Bethesda, Maryland, USA.ORCID 0000-0003-3028-8474

Funding

Cellular organization, division, and differentiation in an ancient, genetically reduced bacteriumR35GM138202 · NIGMS · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · PI GEORGE WARREN LIECHTI · 2020 to 2026
$2.0M
Deutsche Forschungsgemeinschaft 390536577Deutsche Forschungsgemeinschaft 398967434 -TRR261NIGMS NIH HHS GM138202NIGMS NIH HHS R35 GM138202Uniformed Services University of the Health Sciences HP73LIEC18
6 · The paper itself

Abstract

Pathogenic chlamydial species restrict their peptidoglycan (PG) to the division septum of their replicative forms. PG is a microbe-associated molecular pattern, and two of its major pattern recognition receptors in human cells are nucleotide-binding oligomerization domain-containing proteins 1 and 2 (NOD1 and NOD2, respectively). It has been proposed that this unique morphological feature is evidence of pathoadaptation by the microbe, permitting PG-dependent cell division while also reducing the bacterium's recognition by innate immune receptors.

Indexed as

Chlamydia InfectionsChlamydia trachomatisNod2 Signaling Adaptor ProteinSignal TransductionAnimalsChlamydia muridarumHost-Pathogen InteractionsHumansMiceNod1 Signaling Adaptor ProteinPeptidoglycanNod1 Signaling Adaptor ProteinNOD2 protein, humanNod2 Signaling Adaptor ProteinPeptidoglycanChlamydiainnate immunityNOD2pathoadaptationpeptidoglycanpersistence

Identifiers

PMID41416804
PMCPMC12890027

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.